JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

BACTERIOPHAGE AGAINST *STAPHYLOCOCCUS AUREUS* BACTERIA

Rajeev Ranjan[1], Sanjana Kushwaha[2], Rahul Patel[3], Manish Kumar Singh[*]

[1*]Department of Biotechnology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India

[2,3]Department of Microbiology, Dr. Ram Manohar Lohia Avadh University, Ayodhya, Uttar Pradesh India

Abstract

The increasing prevalence of antibiotic-resistant Staphylococcus aureus, particularly Methicillin-resistant *S. aureus* (MRSA), poses a serious public health challenge worldwide. This study investigates the potential of bacteriophages as an alternative or complementary treatment to conventional antibiotics. Bacteriophages are viruses that specifically infect and kill bacteria without harming human cells, making them promising agents in the fight against resistant bacterial strains. The paper explores the biology of bacteriophages, including their specificity, replication mechanisms, and lifecycle, with a focus on their application against *S. aureus*. Experimental evidence from laboratory and clinical studies is examined to demonstrate their effectiveness in reducing bacterial load and disrupting biofilms associated with chronic infections. The study also discusses the advantages of phage therapy, such as minimal side effects, adaptability to bacterial mutations, and targeted action that spares beneficial microbiota. However, it also addresses potential limitations, including the development of phage-resistant bacteria, regulatory concerns, and immune system interactions. Despite these challenges, bacteriophage therapy shows great potential as a novel antimicrobial strategy. The study concludes by emphasizing the need for more research, standardized protocols, and clinical trials to fully integrate phage therapy into mainstream medical practice as a sustainable solution to antibiotic resistance.

Keywords: Bacteriophage, Antibiotic, Drug resistance, Pathogen, Bacteria

Introduction

Bacteriophage Therapy Against *Staphylococcus aureus* Bacteriophage therapy, a novel approach utilizing viruses that specifically target and lyse bacterial cells, has emerged as a promising alternative to traditional antibiotics, particularly in the fight against antibiotic-resistant infections such as those caused by *Staphylococcus aureus*. As antibiotic resistance continues to escalate, the efficacy of phages in treating serious infections, including those affecting the bloodstream, highlights their potential role in modern medicine[1][2][3]. *Staphylococcus aureus*, especially methicillin-resistant strains (MRSA), poses significant challenges in clinical settings due to its ability to develop resistance against multiple antibiotics, necessitating the exploration of alternative treatment modalities(Kim *et al.*, 2025). Phages act by attaching to bacterial cells, injecting their genetic material, and subsequently causing cell lysis. This targeted action minimizes harm to human cells while effectively combating the pathogen [5][6]. Moreover, phage therapy has shown promise in disrupting biofilms clusters of bacteria that are notoriously resistant to conventional antibiotics demonstrating superior efficacy in treating chronic *S. aureus* infections(Noor *et al.*, 2024). The combination of phage therapy with antibiotics has further revealed synergistic effects, enhancing the overall treatment outcome against resistant strains [8][9]. Despite its potential, the integration of phage therapy into clinical practice faces several challenges. The emergence of phage-resistant bacterial strains, the need for personalized phage preparations, and regulatory hurdles complicate the application of this innovative therapy in conventional healthcare

settings [10][11][12]. Additionally, the dynamic nature of phage interactions with bacterial populations requires a shift from traditional pharmaceutical regulations, which may not adequately address the complexities of biologics[11][13]. Ongoing research is essential to navigate these challenges and to establish clear regulatory pathways, enabling the broader use of phage therapy against *S. aureus* infections. Advances in phage genome engineering and personalized treatment approaches hold significant promise for enhancing the therapeutic landscape in the face of rising antibiotic resistance, potentially transforming the management of bacterial infections in the future [14][15][16]. Bacteriophages, commonly referred to as phages, are viruses that specifically infect bacterial cells, utilizing the host's cellular machinery for replication. This distinctive mode of action offers substantial potential for addressing the escalating crisis of antibiotic-resistant bacterial infections, particularly in clinical settings where pathogens like *Staphylococcus aureus* pose significant challenges[1][2]. There are two primary types of bacteriophages temperate phages and lytic phages. Temperate phages integrate their genetic material into the host's genome, where it can remain dormant until conditions trigger its activation. Conversely, lytic phages hijack the bacterium's metabolic processes to produce new phages, leading to bacterial cell lysis and the release of progeny phages into the surrounding environment. This process can happen immediately, characteristic of the lytic cycle, or may be delayed as seen in the lysogenic cycle [10][17]. Mechanisms of the action of bacteriophages begin with their attachment to specific receptor proteins on the surface of bacterial cells, initiating the infection process. Following the introduction of their genetic material, phages either cause the bacterium to lyse immediately or enter a latent state, depending on the type of phage involved [6][18]. Lysis, mediated by phage endolysins, not only results in bacterial death but also facilitates the dispersal of new phages, which can target and infect nearby bacterial cells [18][19]. Phage therapy has emerged as a promising alternative to traditional antibiotics, especially in light of the growing incidence of antibiotic resistance. The therapeutic application of bacteriophages includes their ability to disrupt biofilms formed by bacteria on surfaces such as surgical equipment, which is particularly pertinent in the case of *Staphylococcus aureus* [2][20].



figure-1: bacteriophage lytic cycle

Phage therapy can also enhance immune responses by activating both innate and adaptive immunity, providing a multifaceted approach to combat infections [8][21]. Notably, studies have reported no adverse effects associated with phage therapy, suggesting a favourable safety profile[2][17]. Challenges and future directions despite the promise shown by phage therapy, challenges remain. The complexity of immune responses, potential selection for phage-resistant bacterial strains, and the need for tailored phage preparations can complicate treatment regimens[22][23]. As

the prevalence of antibiotic resistance continues to grow, there is an urgent need for research focused on developing effective phage-based therapies as alternatives or adjuncts to traditional antimicrobial treatment[5][18].

Staphylococcus aureus is a significant pathogen frequently encountered in nosocomial (hospital-acquired) environments where the risk of infection transmission is heightened, particularly among immunocompromised patients and healthcare personnel who have extensive contact with them [6][24]. The pathogen is notorious for its ability to develop antibiotic resistance, with methicillin-resistant *S. aureus* (MRSA) being a prominent public health concern since its emergence (Kim *et al.*, 2025). Mechanisms of infection of *S. aureus* can be attributed to a variety of genetic factors that facilitate infection. These factors can be classified into three main categories: immuno modulators, adhesins, and toxins. Immuno modulators are proteins that inhibit the host's immune response, allowing the bacterium to evade detection (Li, Zheng and Leung, 2023). Adhesins, on the other hand, are surface proteins that enable *S. aureus* to attach to various host tissues, thus promoting colonization and infection [4][24]. Toxins are secreted proteins that damage host tissues; notable examples include ±-toxin, ³-toxin, and phenol-soluble modulins (PSMs) which are commonly encoded by the core genome of many *S. aureus* strains (Fowoyo, 2024). The genetic diversity observed among different *S. aureus* strains is largely driven by mobile genetic elements, including bacteriophages, which can introduce virulence factors into the bacterial genome (Green *et al.*, 2023).

Alternative Treatment Approaches

Due to the escalating issue of antibiotic resistance, there has been an increasing interest in alternative therapeutic strategies. These include the use of antimicrobials such as bacteriocins, bacteriophages (phages), and phage endolysins. These alternatives present a significant advantage over conventional antibiotics, as many of these agents possess narrow inhibition spectra. This selectivity allows for targeted treatment of pathogenic bacteria while sparing commensal organisms, thereby minimizing collateral damage to the host microbiome [4][5][6]. Bacteriophage therapy has emerged as a promising alternative to traditional antibi otics in the fight against antibiotic-resistant infections, particularly those caused by *Staphylococcus aureus*. Recent studies have demonstrated the safety and efficacy of bacteriophage therapy for severe *S. aureus* infections, including those affecting the bloodstream (Lin, Koskella and Lin, 2017).

Mechanisms of Action

Bacteriophages, or phages, are viruses that specifically infect and lyse bacterial cells. Their effectiveness is attributed to their ability to target and kill bacteria while leaving human cells unharmed. Research has indicated that combining bacteriophage therapy with sub therapeutic doses of flucloxacillin can enhance the therapeutic effects against *S. aureus* infections, suggesting a synergistic interaction between phages and antibiotics (Fowoyo, 2024). Efficacy against biofilms is one of the significant challenges in treating *S. aureus* infections is its ability to form biofilms, which are clusters of bacteria encased in a protective matrix. Bacteriophages have shown a higher efficacy in reducing and dispersing *S. aureus* biofilms compared to traditional antibiotics (Oechslin, 2018). This property is particularly important, as biofilms are often associated with chronic infections that are resistant to standard treatments.

Challenges and Considerations

Despite the promising results from case studies and preliminary trials, there remain critical challenges in the application of phage therapy within conventional clinical frameworks. The dynamic nature of phage therapy, which requires rapid adjustments to counteract bacterial evolution, complicates its integration into current regulatory systems designed for static drug products (Hitchcock *et al.*, 2023). The need for comprehensive pre market safety and efficacy data presents additional obstacles, as does the biological complexity inherent in phage preparations, which can vary naturally (Strathdee *et al.*, 2023).

Future Directions Advancements in Phage Therapy

As research continues to evolve, the therapeutic potential of bacteriophages against *Staphylococcus aureus* (*S. aureus*) is gaining momentum. Future studies are expected to focus on the optimization of phage selection processes, emphasizing the use of personalized phage therapy tailored to individual patient infections. Despite the encouraging results from case reports and preliminary studies, there is a pressing need for controlled clinical efficacy trials to validate the effectiveness of this approach in a more systematic manner [6][9][27]. Phage genome engineering is another promising avenue for the future of phage therapy. Current challenges such as narrow host ranges and immunological clearance are being addressed through innovative genetic engineering techniques. Approaches like CRISPR/Cas systems and BRED (Bacteriophage Recombineering of Electroporated DNA) are gaining traction for editing phage genomes, potentially broadening their therapeutic applicability [14][28](‘Building evidence for the use of bacteriophages against antimicrobial resistance’, no date). Furthermore, the production of synthetic phages is rapidly progressing, with the aim of chemical synthesis of entire phage genomes. This could enhance scalability and safety, as it minimizes the risk of contaminating bacterial components in therapeutic products [8][15][30]. Future research may also explore the efficacy of combination therapies, where phage therapy is used in conjunction with traditional antibiotics. Given the rise of antibiotic resistance in *S. aureus* strains, combining the bactericidal effects of phages with antibiotics could yield synergistic effects, improving treatment outcomes [8][9][10]. Finally, as the field advances, establishing clear regulatory pathways for phage therapy will be essential. This will involve collaboration between researchers, healthcare providers, and regulatory bodies to ensure that phage preparations are safe, effective, and accessible to patients [11][16][31]. Creating robust frameworks will facilitate the transition from laboratory research to clinical application, ultimately paving the way for phage therapy to become a mainstream treatment for *S. aureus* infections.

Advantages of Bacteriophage Therapy

Bacteriophage therapy presents a promising alternative to traditional antibiotic treatments, particularly in the face of rising antibiotic resistance. One of the primary advantages of phage therapy is its ability to target and disrupt biofilms formed by bacteria, which are notoriously difficult to treat with conventional antibiotics. Biofilm-related infections are a major clinical challenge, as the bacterial cells embedded within biofilms exhibit heightened tolerance to antibiotic treatment [7][8]. Lytic bacteriophages have evolved to specifically infect and eradicate these biofilm-associated cells, thereby enhancing the efficacy of antibiotic treatment against infections such as those caused by *Staphylococcus aureus* [6][32]. Furthermore, phage therapy has demonstrated a favourable safety profile, with studies indicating a tolerability and treatment-emergent adverse effect rate of 42.9% for phage treatment compared to 50% for placebo (Berryhill *et al.*, 2021). This suggests that phages could potentially serve as a safer alternative for patients, especially those who have limited options due to adverse reactions to traditional antibiotics. Additionally, phage therapy offers the possibility of synergistic interactions when used in combination with antibiotics. Studies have shown that certain phages can augment the effectiveness of antibiotics against biofilm-forming strains of *Staphylococcus aureus* [7][9]. The potential for synergistic effects between phages and antibiotics opens new avenues for treatment strategies, particularly in combating resistant strains. Moreover, bacteriophages can be highly specific to their bacterial hosts, which minimize the disruption of beneficial microbiota present in the human body. This specificity not only reduces the likelihood of side effects associated with broad-spectrum antibiotics but also helps maintain the balance of the microbiome, which is essential for overall health [34][35].

Limitations and Challenges

The use of bacteriophages in the treatment of *Staphylococcus aureus* infections faces several limitations and challenges that must be addressed for successful clinical application. Phage resistance is one of the significant challenges in phage therapy is the emergence of phage resistance among bacterial populations. Bacteria can develop resistance mechanisms that prevent phages from successfully infecting them, leading to treatment failure [6][12]. This resistance may stem from a variety of factors, including genetic mutations or alterations in bacterial surface receptors that phages utilize to attach and infect the cells [21][33]. Additionally, the dynamics of bacterial populations, particularly at low cell densities, complicate treatment, as it has been shown that a larger number of phages are necessary for effective infection under these conditions [36][37]. Integrating phage therapy into existing medical regulations poses significant challenges. Traditional pharmaceutical regulations are designed for static products and are ill-suited to accommodate the dynamic nature of phage therapies, which may require rapid

modifications to respond to evolving bacterial strains [10][11]. Key regulatory hurdles include the demand for extensive premarket safety and efficacy data obtained through large clinical trials, which can be particularly burdensome for targeted therapies like phage treatment (‘Building evidence for the use of bacteriophages against antimicrobial resistance’, no date)(Nang *et al.*, 2023). Furthermore, current manufacturing standards and quality control requirements often fail to account for the biological variability and complexity inherent in phage products, making compliance difficult (‘Building evidence for the use of bacteriophages against antimicrobial resistance’, no date).

The clinical implementation of phage therapy also encounters obstacles related to standardization and delivery methods. Ensuring consistent phage formulation and determining optimal dosing regimens are critical for maximizing therapeutic efficacy (Cui *et al.*, 2019; Subramanian, 2024). Additionally, the potential for adverse immune responses to phage preparations complicates treatment protocols, necessitating thorough preclinical and clinical evaluation (Cui, Watanabe, *et al.*, 2024).

Future Directions

Advancements in phage therapy, as research continue to evolve, the therapeutic potential of bacteriophages against *Staphylococcus aureus* (*S. aureus*) is gaining momentum. Future studies are expected to focus on the optimization of phage selection processes, emphasizing the use of personalized phage therapy tailored to individual patient infections. Despite the encouraging results from case reports and preliminary studies, there is a pressing need for controlled clinical efficacy trials to validate the effectiveness of this approach in a more systematic manner (‘Building evidence for the use of bacteriophages against antimicrobial resistance’, no date) (Vázquez *et al.*, 2022; Liu *et al.*, 2024). Phage genome engineering is another promising avenue for the future of phage therapy. Current challenges such as narrow host ranges and immunological clearance are being addressed through innovative genetic engineering techniques. Approaches like CRISPR/Cas systems and BRED (Bacteriophage Recombineering of Electroporated DNA) are gaining traction for editing phage genomes, potentially broadening their therapeutic applicability (Vázquez *et al.*, 2022; Guo, Yuan and Chai, 2024). Furthermore, the production of synthetic phages is rapidly progressing, with the aim of chemical synthesis of entire phage genomes. This could enhance scalability and safety, as it minimizes the risk of contaminating bacterial components in therapeutic products (Anomaly, 2020; Onsea *et al.*, 2021; Jurado *et al.*, 2022).

Combination therapies, future research may also explore the efficacy of combination therapies, where phage therapy is used in conjunction with traditional antibiotics. Given the rise of antibiotic resistance in *S. aureus* strains, combining the bactericidal effects of phages with antibiotics could yield synergistic effects, improving treatment outcomes (Anomaly, 2020; Hitchcock *et al.*, 2023; Liu *et al.*, 2024). Finally, as the field advances, establishing clear regulatory pathways for phage therapy will be essential. This will involve collaboration between researchers, healthcare providers, and regulatory bodies to ensure that phage preparations are safe, effective, and accessible to patients (Strathdee *et al.*, 2023; Cui, Watanabe, *et al.*, 2024; Uchechukwu and Shonekan, 2024). Creating robust frameworks will facilitate the transition from laboratory research to clinical application, ultimately paving the way for phage therapy to become a mainstream treatment for *S. aureus* infections.

Conclusion

Bacteriophage therapy has emerged as a compelling alternative in the fight against antibiotic-resistant infections, particularly those caused by Staphylococcus aureus, including MRSA strains. This study highlights the unique advantages of phages, such as their specificity to bacterial targets, effectiveness against biofilms, and minimal disruption to beneficial microbiota. Additionally, the potential synergy between bacteriophages and conventional antibiotics could significantly enhance treatment outcomes. However, several challenges persist, including the emergence of phage-resistant bacterial strains, regulatory complexities, and the need for standardized production and delivery protocols. Despite these hurdles, advancements in phage genome engineering, personalized therapy, and synthetic phage production show promise for overcoming current limitations. The success of future clinical implementation depends on the establishment of clear regulatory frameworks, continued research, and collaborative efforts among scientists, clinicians, and policymakers. Overall, bacteriophage therapy holds immense potential to revolutionize the management of bacterial infections in an era of rising antibiotic resistance. With focused investment in research and infrastructure, phage therapy can transition from experimental use to a reliable and sustainable therapeutic option in mainstream medical practice.

References

Anomaly, J. (2020) 'The Future of Phage: Ethical Challenges of Using Phage Therapy to Treat Bacterial Infections', *Public Health Ethics*, 13(1), pp. 82–88. Available at: https://doi.org/10.1093/phe/phaa003.

Atshan, S.S. *et al.* (2023) 'Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections', *Antibiotics*, 12(2), p. 286. Available at: https://doi.org/10.3390/antibiotics12020286.

Berryhill, B.A. *et al.* (2021) 'Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of *Staphylococcus aureus* infections', *Proceedings of the National Academy of Sciences*, 118(10), p. e2008007118. Available at: https://doi.org/10.1073/pnas.2008007118.

Bragg, R. *et al.* (2014) 'Bacteriophages as Potential Treatment Option for Antibiotic Resistant Bacteria', in R. Adhikari and S. Thapa (eds) *Infectious Diseases and Nanomedicine I*. New Delhi: Springer India (Advances in Experimental Medicine and Biology), pp. 97–110. Available at: https://doi.org/10.1007/978-81-322-1777-0_7.

'Building evidence for the use of bacteriophages against antimicrobial resistance' (no date). Available at: https://www.who.int/europe/news/item/25-06-2024-building-evidence-for-the-use-of-bacteriophages-against-antimicrobial-resistance (Accessed: 24 April 2025).

Cui, L., Watanabe, S., *et al.* (2024) 'A Comprehensive Review on Phage Therapy and Phage-Based Drug Development', *Antibiotics*, 13(9), p. 870. Available at: https://doi.org/10.3390/antibiotics13090870.

Cui, L., Kiga, K., *et al.* (2024) 'Current and future directions in bacteriophage research for developing therapeutic innovations', *Scientific Reports*, 14(1), pp. 24404, s41598-024-76427–5. Available at: https://doi.org/10.1038/s41598-024-76427-5.

Cui, Z. *et al.* (2019) 'Exploring the whole standard operating procedure for phage therapy in clinical practice', *Journal of Translational Medicine*, 17(1), p. 373. Available at: https://doi.org/10.1186/s12967-019-2120-z.

Faltus, T. (2024) 'The Medicinal Phage—Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation', *Viruses*, 16(3), p. 443. Available at: https://doi.org/10.3390/v16030443.

Fowoyo, P.T. (2024) 'Phage Therapy: Clinical Applications, Efficacy, and Implementation Hurdles', *The Open Microbiology Journal*, 18(1), p. e18742858281566. Available at: https://doi.org/10.2174/0118742858281566231221045303.

Green, S.I. *et al.* (2023) 'A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes', *Clinical Infectious Diseases*, 77(8), pp. 1079–1091. Available at: https://doi.org/10.1093/cid/ciad335.

Guo, Z., Yuan, M. and Chai, J. (2024) 'Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections', *Heliyon*, 10(14), p. e34849. Available at: https://doi.org/10.1016/j.heliyon.2024.e34849.

Hitchcock, N.M. *et al.* (2023) 'Current Clinical Landscape and Global Potential of Bacteriophage Therapy', *Viruses*, 15(4), p. 1020. Available at: https://doi.org/10.3390/v15041020.

Jurado, A. *et al.* (2022) 'Understanding the Mechanisms That Drive Phage Resistance in Staphylococci to Prevent Phage Therapy Failure', *Viruses*, 14(5), p. 1061. Available at: https://doi.org/10.3390/v14051061.

Kaźmierczak, N. *et al.* (2022) 'Comparative Assessment of Bacteriophage and Antibiotic Activity against Multidrug-Resistant Staphylococcus aureus Biofilms', *International Journal of Molecular Sciences*, 23(3), p. 1274. Available at: https://doi.org/10.3390/ijms23031274.

Kim, M.K. *et al.* (2025) 'Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches', *Journal of Clinical Investigation*, 135(5), p. e187996. Available at: https://doi.org/10.1172/JCI187996.

Li, J., Zheng, H. and Leung, S.S.Y. (2023) 'Potential of bacteriophage therapy in managing Staphylococcus aureus infections during chemotherapy for lung cancer patients', *Scientific Reports*, 13(1), p. 9534. Available at: https://doi.org/10.1038/s41598-023-36749-2.

Lin, D.M., Koskella, B. and Lin, H.C. (2017) 'Phage therapy: An alternative to antibiotics in the age of multi-drug resistance', *World Journal of Gastrointestinal Pharmacology and Therapeutics*, 8(3), p. 162. Available at: https://doi.org/10.4292/wjgpt.v8.i3.162.

Liu, K. *et al.* (2024) 'Bacteriophage therapy for drug-resistant Staphylococcus aureus infections', *Frontiers in Cellular and Infection Microbiology*, 14, p. 1336821. Available at: https://doi.org/10.3389/fcimb.2024.1336821.

Łusiak-Szelachowska, M. *et al.* (2022) 'Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far', *Journal of Biomedical Science*, 29(1), p. 23. Available at: https://doi.org/10.1186/s12929-022-00806-1.

Mishra, V. *et al.* (2024) 'How Phage Therapy Works, Its Advantages and Disadvantages: Mini Review', *Journal of Pure and Applied Microbiology*, 18(1), pp. 177–184. Available at: https://doi.org/10.22207/JPAM.18.1.49.

Mohammadian, F. *et al.* (2022) 'Isolation and evaluation of the efficacy of bacteriophages against multidrug-resistant (MDR), methicillin-resistant (MRSA) and biofilm-producing strains of Staphylococcus aureus recovered from bovine mastitis', *BMC Veterinary Research*, 18(1), p. 406. Available at: https://doi.org/10.1186/s12917-022-03501-3.

Nang, S.C. *et al.* (2023) 'Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation', *Clinical Microbiology and Infection*, 29(6), pp. 702–709. Available at: https://doi.org/10.1016/j.cmi.2023.01.021.

Noor, I. *et al.* (2024) 'Medicinal and immunological aspects of bacteriophage therapy to combat antibiotic resistance', *Exploration of Medicine*, pp. 215–231. Available at: https://doi.org/10.37349/emed.2024.00217.

Oechslin, F. (2018) 'Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy', *Viruses*, 10(7), p. 351. Available at: https://doi.org/10.3390/v10070351.

Onsea, J. *et al.* (2021) 'Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study', *Microbiology Spectrum*. Edited by O.R. Garcia, 9(3), pp. e01736-21. Available at: https://doi.org/10.1128/spectrum.01736-21.

Pires, D.P. *et al.* (2020) 'Current challenges and future opportunities of phage therapy', *FEMS Microbiology Reviews*, 44(6), pp. 684–700. Available at: https://doi.org/10.1093/femsre/fuaa017.

Plumet, L. *et al.* (2022) 'Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials', *Frontiers in Cellular and Infection Microbiology*, 12, p. 907314. Available at: https://doi.org/10.3389/fcimb.2022.907314.

Principi, N., Silvestri, E. and Esposito, S. (2019) 'Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections', *Frontiers in Pharmacology*, 10, p. 513. Available at: https://doi.org/10.3389/fphar.2019.00513.

Ramchandar, N. and Bradley, J.S. (2025) 'Clinical Application of Bacteriophage Therapy in Children', *Pediatrics*, 155(3), p. e2024068838. Available at: https://doi.org/10.1542/peds.2024-068838.

Samir, S. (2023) 'Phages for treatment of Staphylococcus aureus infection', in *Progress in Molecular Biology and Translational Science*. Elsevier, pp. 275–302. Available at: https://doi.org/10.1016/bs.pmbts.2023.03.027.

Sawa, T., Moriyama, K. and Kinoshita, M. (2024) 'Current status of bacteriophage therapy for severe bacterial infections', *Journal of Intensive Care*, 12(1), p. 44. Available at: https://doi.org/10.1186/s40560-024-00759-7.

Strathdee, S.A. *et al.* (2023) 'Phage therapy: From biological mechanisms to future directions', *Cell*, 186(1), pp. 17–31. Available at: https://doi.org/10.1016/j.cell.2022.11.017.

Subramanian, A. (2024) 'Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance', *Frontiers in Microbiology*, 15, p. 1384164. Available at: https://doi.org/10.3389/fmicb.2024.1384164.

Tan, S.Y. and Tatsumura, Y. (2015) 'Alexander Fleming (1881-1955): Discoverer of penicillin', *Singapore Medical Journal*, 56(7), pp. 366–367. Available at: https://doi.org/10.11622/smedj.2015105.

Uchechukwu, C.F. and Shonekan, A. (2024) 'Current status of clinical trials for phage therapy', *Journal of Medical Microbiology*, 73(9). Available at: https://doi.org/10.1099/jmm.0.001895.

Vázquez, R. *et al.* (2022) 'Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain', *Microorganisms*, 10(4), p. 717. Available at: https://doi.org/10.3390/microorganisms10040717.

Vila, M.M.D.C., Balcão, L.M.N. and Balcão, V.M. (2024) 'Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art', *Pharmaceutics*, 16(3), p. 374. Available at: https://doi.org/10.3390/pharmaceutics16030374.

Williams, J. *et al.* (2023) 'Phage Therapy Administration Route, Regimen, and Need for Supplementary Antibiotics in Patients with Chronic Suppurative Lung Disease', *PHAGE*, 4(1), pp. 4–10. Available at: https://doi.org/10.1089/phage.2022.0036.

Zalewska-Piątek, B. (2023) 'Phage Therapy—Challenges, Opportunities and Future Prospects', *Pharmaceuticals*, 16(12), p. 1638. Available at: https://doi.org/10.3390/ph16121638.